Trastuzumab biosimilar(Shanghai Henlius Biotech, Inc.)

HONG KONG, Oct. 16, 2025 /PRNewswire/ -- On 16 October, the 2025 Sustainability Global Leaders Conference was held in Shanghai. Themed "Joining Hands to Address Challenges: Global Action, Innovation, and Sustainable Growth", the Conference brought together approximately 500 guests from China and abroad, including Nobel Prize laureates, Turing Award laureates, as well as executives from Global 500 companies. Wang Qunbin, Co-Chairman of Fosun International, was invited to deliver a keynote speech titled "Innovation-Driven: Fosun's Path to Global Industry Leadership", in which he shared how Fosun has made innovation as its core driving force in pursuing globalization and achieving a win-win between business success and social value. Wang Qunbin said, "As a global innovation-driven consumer group, Fosun has remained true to its original aspiration of 'Contribution to Society' for more than 30 years. We have combined a global perspective with localized operations and integrated technology innovation with social responsibility to forge a sustainable path driven by innovation and led by responsibility." Leveraging innovation to address unmet needs of families worldwide "The greatest innovation is helping people live a life without regrets," said Wang Qunbin. "In the field of health, innovation is not about numbers in academic papers, but hope reflected in the eyes of patients. Behind every unmet medical need is a family longing for good health." He took HANSIZHUANG, an innovative anti-PD-1 monoclonal antibody independently developed by Fosun, as an example to illustrate Fosun's approach to innovation. Lung cancer has the highest morbidity and mortality rates among all malignancies in the world, and small cell lung cancer (SCLC) is the most aggressive subtype. Approximately 80% of SCLC patients are already in the extensive stage at the time of diagnosis, with rapid disease progression and poor overall prognosis. In response to this daunting challenge, Fosun's team of scientists successfully developed HANSIZHUANG, the world's first anti-PD-1 monoclonal antibody approved for the first-line treatment of SCLC. To date, it has been approved for marketing in nearly 40 countries and regions, including China, the European Union (EU), the United Kingdom, Singapore, and India, benefiting more than 110,000 patients worldwide. HANSIZHUANG is the first and currently the only anti-PD-1 monoclonal antibody approved in the EU for the treatment of extensive-stage small cell lung cancer (ES-SCLC). "As a Chinese company, we are very proud. This approval marks the successful entry of Chinese innovative drugs into the world's most stringent pharmaceutical regulatory market," said Wang Qunbin. It is worth noting that on 9 October, the Phase III clinical trial of HANSIZHUANG for perioperative gastric cancer met its primary endpoint, supporting an early drug application for market approval. This achievement suggests that gastric cancer patients may no longer require adjuvant chemotherapy before and after surgery in the future. Since the beginning of this year, Fosun has achieved multiple breakthroughs in the field of innovative drugs. HLX43, a PD-L1-targeting antibody-drug conjugate (ADC) is undergoing clinical studies for solid tumors such as non-small cell lung cancer and thymic carcinoma in countries including China, the United States, Japan, and Australia. Currently, no PD-L1 ADC has been approved globally, positioning HLX43 as a potential highly effective and safe broad-spectrum anticancer drug. Additionally, in the field of innovative small molecule drugs, FUMAINING, a targeted drug independently developed by Fosun, has been approved for two rare disease indications, filling the treatment gap in the field of rare tumors. Wang Qunbin believes that Chinese companies are undergoing a major transformation in the field of innovative drugs, progressing from "following behind", to "running alongside", and now "leading the race". "For Fosun, we will continue to pursue original innovation, focus on addressing unmet clinical needs, and collaborate with global partners to advance healthcare development together." Leveraging innovation to participate in global value creation As one of the earliest Chinese private enterprises to go global, Fosun has maintained a deep presence in more than 40 countries and regions worldwide. Wang Qunbin stated, "We deeply understand that the core of globalization capability lies in innovation and the ability to integrate the value chain." In pharmaceuticals, Fosun has consistently aligned its strategy with globalization. After more than a decade of development, it has gradually built global capabilities in research and development (R&D), regulatory approval, business development (BD), and marketing. To date, Fosun's innovative biopharmaceutical products have reached nearly 60 countries and regions, benefiting more than 850,000 patients worldwide. Among them, HANQUYOU, a core product in breast cancer treatment, is a China-developed monoclonal antibody biosimilar approved in China, the EU, and the United States. It has been approved for marketing in more than 50 countries and regions worldwide. Regarding global R&D, Fosun has established a leading platform for innovative small molecule drugs, a platform for large molecule technologies including antibodies and ADCs, a cell therapy platform, and a forward-looking nuclear medicine platform. Henlius, which focuses on large molecules, has filed over 800 drug regulatory applications globally and secured more than 600 approvals. Regarding global BD, Fosun has forged long-term strategic partnerships with Abbott, Dr. Reddy's, Lotus, Sandoz, and others, accelerating expansion in key markets. In the first half of this year, Henlius' cash inflows from BD agreements exceeded RMB1 billion, surging 280% year-on-year. In August 2025, two small molecule inhibitors independently developed by Fosun Pharma were consecutively licensed out, collaborating with overseas partners to benefit more patients globally. Fosun's global innovation extends beyond pharmaceuticals. Wang Qunbin shared that in the field of cultural tourism and consumption, Fosun Tourism Group's (FTG) Club Med have continued to advance AI-driven digital transformation. The G.M Copilot conversational AI assistant, which provides 24/7 instant and personalized service, has already expanded to 12 markets worldwide, including Brazil, France, Belgium, Singapore, and Malaysia. In August 2025, FTG entered into a full-stack AI collaboration with Alibaba Cloud to jointly develop the cultural tourism intelligent system, "AI G.O", based on Tongyi Qianwen (Qwen) models, substantially enhancing the end-to-end vacation experience for customers worldwide. In the field of financial services, Fosun Insurance Portugal has leveraged AI applications to comprehensively improve the efficiency of its entire business process and enhance data accuracy, driving rapid growth of its insurance business. Currently, the rate of fully automated processing for motor claims has risen from 48% at the end of 2023 to 66%. In addition, the Yuyuan Lantern Festival has expanded internationally, with events held successively in Paris, France, and Bangkok, Thailand, offering new opportunities for international audience to discover and appreciate Chinese culture. Meanwhile, Shede Spirits, embodying the Chinese wisdom of "giving and receiving", has expanded its global footprint, now available in 40 countries and regions. "Innovation is the fundamental driving force of value creation. We firmly believe that consistently generating value through innovation is the cornerstone for Chinese companies to go global," said Wang Qunbin. Leveraging innovation to advance global corporate social responsibility "Enterprises are not only commercial entities but also social citizens. We believe that developing business for good lays the foundation for sustainable corporate development. Innovation is not just a technological breakthrough but a redesign of solutions to social issues," said Wang Qunbin. Over more than 30 years of development, Fosun has consistently prioritized ESG (Environmental, Social, and Governance) responsibilities. In the fight against malaria worldwide, Fosun has consistently contributed the "China Solution", developing artemisinin discovered by Nobel Prize laureate Tu Youyou's team into China's first two innovative drugs, China no. 001 (artesunate) and no. 002 (artesunate for injection). As at the end of June 2025, Fosun had supplied a cumulative total of over 420 million doses of artesunate for injection globally, saving the lives of more than 84 million patients with severe malaria worldwide. Despite significant global progress against malaria in recent decades, it remains a major public health challenge, especially in sub-Saharan Africa where malaria claims a life every minute. According to the World Health Organization's (WHO) World Malaria Report 2024, there were an estimated 263 million new malaria cases in 83 countries and 597,000 malaria deaths worldwide in 2023. Facing this daunting challenge, Fosun continues to innovate and strives to enhance drug accessibility. In June 2023, Fosun's second-generation artesunate for injection, Argesun, received WHO prequalification (WHO-PQ), becoming the first artesunate injectable presented with a single solvent system approved by WHO-PQ. Compared with the first generation, the second generation greatly improves clinical convenience and is particularly suited for remote areas in Africa with limited medical infrastructure. It is hailed by local healthcare workers as a "life-saving medicine from China". Similarly, centered on the global public health issue, Fosun launched the Rural Doctors Program in China's rural areas in 2017. Guided by the principle, "We support rural doctors, and rural doctors protect all", the Program has, after eight years of persistent effort, covered 78 counties in 16 provinces, cities, and autonomous regions, supported 25,000 rural doctors and benefited more than 16 million rural residents and 3 million rural families. In September this year, the "Healthy China • 2025 National Warm-Hearted Rural Doctors and Township Hospital Directors" award ceremony took place at Tsinghua University. During the event, the AI Rural Doctor Assistant (version 1.0) was unveiled. Developed using Alibaba's Tongyi large model, this tool transforms the Rural Doctor's Pocket Guide, a clinical reference jointly compiled by experts, into a digital database. Rural doctors can efficiently consult evidence-based, inclusive primary care protocols through a simple Q&A interface, enhancing their daily work efficiency. "When every rural doctor in China and every child in Africa can benefit from the most important innovative dividends of our era, our innovation achieves its greatest value," said Wang Qunbin. "'Contribution to Society' has been Fosun's corporate value since its establishment. Whether through providing artesunate to aid the fight against malaria in Africa or implementing the Rural Doctors Program, these initiatives embody this value in action." Thanks to years of sustained effort, Fosun has maintained an MSCI ESG rating of AA, and has been repeatedly included in the S&P Global's Sustainability Yearbook, ranking among the top 1% of Chinese companies. Its FTSE Russell ESG score has also continued to lead its global peers. Wang Qunbin stated that on the path to sustainable development, the power of "business for good" is driving profound changes among enterprises and societies, both in China and globally, under the vision of a community with a shared future for mankind. "Looking ahead, Fosun will join hands with global partners, leveraging innovation as the ladder and responsibility as the rope to continue climbing new heights in sustainable development, contributing the wisdom and strength of Chinese enterprises to the community with a shared future for mankind." SOURCE Fosun WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

10月16日，2025可持续全球领导者大会在上海举行。大会以“携手应对挑战：全球行动、创新与可持续增长”为主题，包括诺贝尔奖得主、图灵奖得主、全球500强企业负责人等在内的约500位中外嘉宾参会。 复星国际联席董事长汪群斌应邀作题为《以创新驱动：复星全球化攀登之路》的演讲，分享了复星如何在全球化征程中，以创新为核心驱动力，实现商业价值与社会价值的双赢。 汪群斌表示： 作为一家创新驱动的全球家庭消费产业集团，复星成立三十余年来始终秉持‘助天下’的初心，将全球化视野与本地化深耕相结合，将科技创新与社会责任相融合，走出一条创新驱动、责任引领的可持续发展之路。 “创新的最高境界，是让生命不留遗憾。”汪群斌表示，“在健康领域，创新不是论文上的数字，而是患者眼中的希望。每一个未被满足的医疗需求背后，都是一个渴望健康的家庭。” 他以复星自主研发的创新型抗PD-1单抗H药汉斯状为例，进一步阐释复星对创新的理解。 肺癌是全球发病率和死亡率最高的恶性肿瘤，而小细胞肺癌是其中侵袭性最强的亚型，约80%的患者首次确诊时已处于广泛期阶段，临床病情恶化快，总体预后不良。 面对这一严峻挑战，复星的科学家团队成功研发出H药——全球首个获批用于一线治疗小细胞肺癌的抗PD-1单抗。截至目前，H药已在中国、欧盟、英国、新加坡、印度等近40个国家和地区获批上市，惠及全球逾11万名患者。 H药是首个且目前唯一在欧盟获批用于广泛期小细胞肺癌治疗的抗PD-1单抗。“作为中国企业，我们感到很自豪，这意味着中国创新药成功进入了全球药品审批最严格的市场。”汪群斌说。 值得一提的是，10月9日，H药胃癌围手术期III期临床研究达到了主要终点，支持提前申报上市。这意味着，未来，胃癌患者在术前和术后有望不再需要进行辅助化疗。 今年以来，复星在创新药领域实现多点破局。HLX43是一款靶向PD-L1的抗体偶联药物（ADC），正在中、美、日、澳等国家开展非小细胞肺癌、胸腺癌等实体瘤的临床研究。目前，全球范围内尚无PD-L1 ADC获批上市，HLX43有潜力成为高效、安全的“广谱抗癌药”。此外，在小分子创新药方面，复星自研的靶向药物复迈宁获批两项罕见病适应症，填补了相关罕见病肿瘤领域的治疗空白。 汪群斌认为，在创新药赛道，从“跟跑”到“并跑”再到“领跑”，中国企业正在经历一次伟大的转型，“就复星而言，我们将继续以源头创新为目标，聚焦未满足的临床需求，携手全球合作伙伴共同推动医疗健康事业发展。” 作为最早“出海”的中国民营企业之一，复星在全球超过40个国家和地区持续深耕。汪群斌表示：“我们深刻体会到，全球化能力的核心是创新能力，是价值链整合的能力。” 在医药领域，复星始终瞄准全球化进行布局。经过十多年积累，逐步构建起全球化的研发、注册、BD（业务发展）和营销能力。截至目前，复星旗下生物药创新产品已触达近60个国家和地区，惠及全球超85万患者。其中，乳腺癌治疗核心产品汉曲优，是中国、欧盟、美国获批的“中国籍”单抗生物类似药，累计在全球50多个国家和地区获批上市。 ▲截止至2025年7月，汉曲优全球发货750多万支，惠及全球超过26万患者 在全球研发方面，复星打造了领先的小分子创新药平台，抗体、ADC等大分子技术平台，细胞治疗技术平台，并前瞻布局核药技术平台。专注于大分子的复宏汉霖已在全球范围内完成800余项药政注册申请，并获得600余项批准。 在全球BD方面，复星长期与Abbott、Dr. Reddy's、Lotus、Sandoz等通过战略合作，加速拓展全球主要市场。今年上半年，复宏汉霖BD合同现金流入超10亿元，同比增长280%。今年8月，复星医药两款自研的小分子抑制剂也连续实现对外授权，将携手海外合作伙伴，惠及更多全球患者。 复星的全球化创新不止于医药领域。汪群斌介绍，在文旅消费领域，复星旅文Club Med地中海俱乐部持续深化AI数字化升级，G.M Copilot对话助手提供7x24小时即时响应的个性化服务，目前已覆盖巴西、法国、比利时、新加坡、马来西亚等全球12个国家市场。今年8月，复星旅文与阿里云达成全栈AI合作，基于通义千问模型共同开发文旅智能体“AI G.O”，全球客户的度假全流程体验将得到大幅提升。 在金融服务领域，复星葡萄牙保险依托AI应用，全面提升业务全流程效率，并提高数据准确性，推动保险业务快速发展。目前，车险自动理赔率从2023年末的48%提升至66%。 此外，豫园灯会走出国门，相继在法国巴黎、泰国曼谷举办，为海外朋友了解中国文化、爱上中国文化，打开了新的窗口。舍得酒业也承载着“舍与得”的中国智慧，扬帆出海，登陆40个国际和地区。 “创新是价值创造的源动力。我们始终相信，依托创新不断实现价值创造，是中国企业出海最重要的锚。”汪群斌说。 “企业不仅是商业主体，更是社会公民。我们相信，商业向善是企业可持续发展的基石，创新不仅是技术突破，更是社会问题解决方案的重新设计。”汪群斌表示，在30多年的发展历程中，复星始终高度重视ESG（环境、社会、治理）责任。 在抗击全球疟疾方面，复星持续贡献“中国方案”，将诺贝尔奖得主屠呦呦团队发现的青蒿素，研发成为中国001号（青蒿琥酯）、002号（注射用青蒿琥酯）创新药。截至2025年6月底，复星已累计向全球供应超过4.2亿支注射用青蒿琥酯，累计救治全球超8400万重症疟疾患者。 过去数十年间，尽管全球抗疟取得了重大进展，疟疾仍然是全球主要公共卫生问题之一，特别是在撒哈拉以南非洲，疟疾每分钟就夺走一个人的生命。根据世界卫生组织《2024年世界疟疾报告》，2023年全球83个国家估计有2.63亿新发疟疾病例，全球疟疾死亡人数达到59.7万人。 面对这一严峻挑战，复星持续创新，尽最大努力提升药品可及性。2023年6月，复星自主研发的第二代注射用青蒿琥酯Argesun获世界卫生组织预认证，成为首个通过该预认证的一步配制青蒿琥酯注射剂。与第一代产品相比，第二代产品极大提升了临床使用的便利性，特别适用于医疗条件相对落后的非洲偏远地区，被当地医护人员称为“来自中国的救命药”。 ▲复星医药子公司Tridem Pharma首个非洲区域性药品分销中心已在科特迪瓦投入运营，为医疗健康产品在非洲地区的持续可及性提供保障。 同样围绕“健康”这个全球公共议题，在中国乡村，复星于2017年发起了乡村医生项目。秉持“我们守护村医，村医守护大家”理念，经过8年坚持，乡村医生项目已覆盖16个省、市、自治区的78个县，守护着2.5万名村医，惠及300万户农村家庭、超1600万农村人口。 今年9月，“健康中国·2025全国暖心乡村医生及乡镇卫生院院长”发布仪式在清华大学举行。会上推出了AI村医助手（1.0），它依托阿里巴巴通义大模型打造，把专家们共同编写的《乡村医生诊疗口袋书》转化为数字数据库，村医可以通过简洁的窗口，一问一答，随时查阅口袋书中权威、普惠的基层医疗问诊方案，高效辅助日常工作。 “当每位中国村医、每位非洲儿童都能享受到这个时代最重要的创新红利，我们的创新就有了最大价值。”汪群斌表示，“‘助天下’是复星成立之初就确立的企业价值观，无论青蒿琥酯援非抗疟，还是乡村医生项目，都是这一理念的具体实践。” 凭借多年来的持续努力，复星MSCI ESG评级保持为AA，连续入选标普全球《可持续发展年鉴》，并在中国企业中名列最佳1%，富时罗素ESG评分也持续领先全球同业。 汪群斌表示，在可持续发展道路上，商业向善的力量正在推动企业与社会、中国与世界，在命运共同体的理念下发生深刻变革，“未来，复星将携手全球合作伙伴，以创新为梯，以责任为缆，继续攀登可持续发展的新高峰，为人类命运共同体贡献中国企业的智慧与力量。”